Drug Development

News, research & analysis from the global Drug Development and pharmaceutical industries.

April 12, 2017

GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

[vc_row][vc_column][vc_column_text]GE Healthcare recently announced the acquisition of British cryogenic processing company Asymptote for an undisclosed price, strengthening its cell therapy portfolio with technologies designed to enable […]
March 2, 2017

The Antibody Quality Conundrum: Abcam Ahead of the Curve with Knockout Validation

[vc_row][vc_column][vc_column_text] In September 2016 the International Working Group for Antibody Validation (IWGAV) finally announced their five conceptual pillars, outlining recommendations to mitigate the antibody specificity and […]
February 20, 2017

Pharmaron Continue Their Global Expansion with Grand Opening of Hoddesdon Facility

[vc_row][vc_column][vc_column_text] Fully integrated contract research and manufacturing organisation Pharmaron have formally opened their Hoddesdon facility, making it the first Sino-US CRO to operate in each major […]
January 27, 2017

Lonza Accelerates its “Healthcare Continuum” Strategy with $5.5B Acquisition of Capsugel

[vc_row][vc_column][vc_column_text] At the end of 2016 Lonza entered into an agreement to acquire Capsugel for $5.5B in cash, including refinancing of $2B of existing Capsugel debt. […]
January 12, 2017

Drug Development IPO Analysis: Over $4.2B Raised Globally in Q4 2016 Despite Continued NASDAQ Decline

[vc_row][vc_column][vc_column_text] Whilst the depression in the value and frequency of Drug Development IPOs on the NASDAQ market continued throughout the fourth quarter of 2016, a combined […]
November 29, 2016

Promising Autologous CAR-T Cell Therapies Stumble: is this the End, or Just the Beginning?

[vc_row][vc_column][vc_column_text]The field of CAR-T immunotherapy presents a tantalising idea: reengineering a patient’s immune cells to attack cancer. CAR-T immunotherapy has the potential to revolutionise the way […]